Skip to content

AntiDFS70 Lupus Nephritis

Anti-DFS70 Antibodies and it's Relationship With Systemic Lupus Erythematosus Manifestations

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06119763
Enrollment
50
Registered
2023-11-07
Start date
2023-10-15
Completion date
2024-10-25
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

Systemic lupus erythematous (SLE) is a heterogeneous autoimmune disease that involve many different organs and display a variable clinical course. The prevalence of SLE varies across gender, race/ethnicity, and geographic regions. SLE demonstrates a striking female predominance with a peak incidence of disease during the Reproductive years. In adults, the female to male ratio is 10- 15:1(1)( 2) Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe, life-threatening internal organ disease. Constitutional symptoms, rash, mucosal ulcers, inflammatory polyarthritis, photosensitivity, and serositis are the most common clinical features of the disease. (3) (4) Anti-DFS70 antibodie) and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies , there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of antinuclear antibodies associated rheumatic diseases. (8) Anti-DFS70 antibodies were not associated with lupus nephritis development in Systemic lupus erythematosus patients but were associated with anti-dsDNA antibodies , proliferative lupus nephritis, and renal activity index . This suggests their potential to serve as a non-histological biomarker for lupus nephritis subclass and activity status. (8)

Interventions

DIAGNOSTIC_TESTanti dfs70 antibodies

blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

1. Patients who fulfill the 2019 American College of Rheumatology/European League against Rheumatism classification criteria of Systemic Lupus Erythematous . (9) 2. Patients who is able to give informed consent to join the study. •

Exclusion criteria

\- \- Any patient with any collagen disease other than systemic lupus erythematous

Design outcomes

Primary

MeasureTime frameDescription
antiDFS70 antibodies titre1 yearserve as a non-histological biomarker for lupus nephritis subclass and activity status.

Countries

Egypt

Contacts

Primary Contactashrakat s Mohammed, resident
ashraketshaaban@med.sohag.edu.eg01005046015
Backup ContactEssam m abo el fadl, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026